Oxidative Stress Mechanisms and Parkinson's Disease Treatment

A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 866

Special Issue Editor


E-Mail Website
Guest Editor
Facultat de Medicina, University of Chile, Santiago 8330111, Chile
Interests: Parkinson's disease; neuromelanin; neuroprotection; neurodegeneration; dopamine oxidation; preclinical model for Parkinson's disease

Special Issue Information

Dear Colleagues,

It has been 57 years since the introduction of L-dopa in the treatment of idiopathic Parkinson's disease, and it is still the most effective drug in the treatment of this disease despite severe side effects after chronic treatment for 4 to 6 years. However, the failure of clinical studies involving antioxidants such as coenzyme Q raises the need for a thorough analysis of the role of oxidative stress in triggering the loss of neuromelanin-containing dopaminergic neurons of the nigrostriatal system, as well as possible factors that have influenced the failure of these clinical studies. In addition to the role of oxidative stress in the loss of dopaminergic neurons containing neuromelanin from the nigrostriatal system, other mechanisms are also involved, such as the formation of neurotoxic oligomers of alpha-synuclein, mitochondrial dysfunction, endoplasmic reticulum stress, dysfunction of both lysosomal and proteasomal protein degradation systems, and neuroinflammation. Therefore, in order to develop new treatments for idiopathic Parkinson's disease, a critical discussion of both the mechanisms that trigger the loss of neuromelanin-containing dopaminergic neurons from the nigrostriatal system and the preclinical models that we use to evaluate the effectiveness of a drug in this disease is required.

I invite you to submit your latest research findings, hypothesis papers, and review articles to this Special Issue, which will help us both to understand the failure of these clinical studies and to shed light on how to search for new drugs that can halt or modify the progression of this disease.

Prof. Dr. Juan Segura-Aguilar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Parkinson’s disease
  • dopamine
  • dopamine oxidation
  • neuromelanin
  • dopaminergic neurons
  • antioxidants
  • neuroprotection
  • neurodegeneration
  • oxidative stress
  • protein degradation dysfunction
  • neuroinflammation
  • mitochondrial dysfunction
  • endoplasmic reticulum stress
  • alpha-synuclein oligomers
  • glutathione
  • glutathione transferase
  • DT-diaphorase
  • preclinical model for Parkinson's disease
  • VMAT2
  • dopamine transporter
  • tyrosine hydroxylase
  • dopamine-derived orto-quinones

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 2772 KiB  
Article
Evaluation of Additive Neuroprotective Effect of Combination Therapy for Parkinson’s Disease Using In Vitro Models
by Alexander Shtilbans, Elise Esneault, Florian Simon, Joseph R. Mazzulli, Drew J. Quiriconi, Dror Rom, Wolfgang E. Reintsch, Andrea I. Krahn and Thomas M. Durcan
Antioxidants 2025, 14(4), 396; https://doi.org/10.3390/antiox14040396 - 27 Mar 2025
Viewed by 640
Abstract
Background: All the processes leading to neurodegeneration cannot be addressed with just one medication. Combinations of drugs affecting various disease mechanisms concurrently could demonstrate improved effect in slowing the course of Parkinson’s disease (PD). Objective: This was a drug-repurposing experiment designed to assess [...] Read more.
Background: All the processes leading to neurodegeneration cannot be addressed with just one medication. Combinations of drugs affecting various disease mechanisms concurrently could demonstrate improved effect in slowing the course of Parkinson’s disease (PD). Objective: This was a drug-repurposing experiment designed to assess several combinations of nine drugs for possible added or synergistic efficacy using in vitro models of PD. Methods: We evaluated 44 combinations of the nine medications (sodium phenylbutyrate, terazosin, exenatide, ambroxol, deferiprone, coenzyme-Q10, creatine, dasatinib and tauroursodeoxycholic acid) selected for their previously demonstrated evidence of their impact on different targets, showing neuroprotective properties in preclinical models of PD. We utilized wild-type induced pluripotent stem-cell-derived human dopaminergic neurons treated with 1-methyl-4-phenylpyridinium for initial screening. We retested some combinations using an idiopathic PD patient-derived induced pluripotent stem cell line and alpha-synuclein triplication line. We assessed anti-neuroinflammatory effects using human microglia cells. As metrics, we evaluated neurite length, number of branch points per mm2, the number of live neurons, neurofilament heavy chain and pro-inflammatory cytokines. Results: We have identified four combinations of two to three drugs that showed an additive protective effect in some endpoints. Only the combination of sodium phenylbutyrate, exenatide and tauroursodeoxycholic acid showed improvement in four endpoints studied. Conclusions: We demonstrated that some of the medications, used in combination, can exert an additive neuroprotective effect in preclinical models of PD that is superior to that of each of the compounds individually. This project can lead to the development of the first treatment for PD that can slow or prevent its progression. Full article
(This article belongs to the Special Issue Oxidative Stress Mechanisms and Parkinson's Disease Treatment)
Show Figures

Figure 1

Back to TopTop